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Abstract
Summary Growth hormone (GH) treatment in young adults
with childhood-onset GH deficiency has beneficial effects
on bone mass. The present study shows that cortical bone
dimensions also benefit from GH treatment, with endosteal
expansion and increased cortical thickness leading to
improved bone strength.
Introduction In young adults with childhood-onset growth
hormone deficiency (COGHD), GH treatment after final height
is reached has been shown to have beneficial effects on spine
and hip bone mineral density. The objective of the study was to
evaluate the influence of GH on cortical bone dimensions.
Methods Patients (n=160; mean age, 21.2 years; 63%
males) with CO GHD were randomised 2:1 to GH or no
treatment for 24 months. Cortical bone dimensions were
evaluated by digital x-ray radiogrammetry of the metacar-
pal bones every 6 months.
Results After 24 months, cortical thickness was increased
compared with the controls (6.43%, CI 3.34 to 9.61%; p=
0.0001) and metacarpal index (MCI) (6.14%, CI 3.95 to
8.38%; p<0.0001), while the endosteal diameter decreased
(−4.64%, CI −7.15 to −2.05; p<0.001). Total bone width did
not change significantly (0.68%, CI −1.17 to 2.57%; not
significant (NS)). A gender effect was seen on bone width
(p<0.0001), endosteal diameter (p<0.01) and cortical
thickness (p<0.01), but not with MCI (NS).
Conclusions Cortical bone reacts promptly to reinstitution
of GH beyond the attainment of final height by increasing
the cortical thickness through endosteal bone growth. This
leads to a higher peak bone mass and may reduce the risk of
cortical bone fragility later in life.
Keywords Bone strength . Cortical bone . Growth hormone
deficiency . Growth hormone treatment . Metacarpal index
Introduction
Young adults with childhood-onset growth hormone defi-
ciency (CO GHD) have lower bone mineral density than
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healthy controls [1, 2], displaying reduced cortical thick-
ness, cortical cross-sectional area and overall cortical
mineral content [3]. Accordingly, an increased susceptibil-
ity to fractures compared to population controls has been
described in young adults with CO GHD [4–6].
Until recently, patients with CO GHD were only treated
with growth hormone (GH) until final adult height was
attained, usually up until the age of 15–20 years. The
achievement of final adult height, however, occurs much
earlier than the acquisition of peak bone mass and muscle
strength in both genders, with males achieving these
milestones later than females [7]. During the last few years,
it has been shown that in addition to stimulating linear
growth, GH therapy has important beneficial effects on the
accrual of lean body mass and bone mineralisation, past the
years of achieving adult height [8]. Indeed, the impact of
GH on bone mass accrual can continue even after
discontinuation of therapy for over 1.5 years [9]. These
observations suggest that GH treatment should be contin-
ued up to the achievement of peak bone mass.
An increase in bone mass in young adults with GHD
following GH treatment has been reported in several but not
all studies [10, 11]. In adolescents with GHD, Drake et al.
reported that continuation of GH therapy after completion
of linear growth was associated with a greater accrual of
bone mass than no treatment [11]. Most studies have
evaluated the effect of GH on trabecular bone compart-
ments (lumbar spine) or regions with mixed bone structure
(hip) rather than on cortical bone [12]. In one study,
12 months of GH therapy in adults with CO GHD was
associated with increased cortical bone thickness, bone
formation and remodelling activity [12], but there are only
few data on the effects of GH supplementation on the
cortical bone compartment in young adolescents with CO
GHD.
Here we report the findings from a randomised con-
trolled study in which digital x-ray radiogrammetry (DXR)
was used to evaluate changes in the cortical bone
dimensions of the metacarpals following reintroduction of
GH treatment for 24 months in young adults with
confirmed CO GHD after final height was attained.
Methods
Study design
This was part of a randomised, controlled, open-label study
conducted at 22 sites in 12 countries (Australia, Belgium,
France, Germany, Hungary, New Zealand, Norway, Poland,
Spain, Sweden, Switzerland, UK) [13]. The primary
objective of the study was to evaluate the effect of
24 months of GH treatment in young adults with CO
GHD on bone mineral density (BMD) in the lumbar spine
and hip using dual energy X-ray absorptiometry. In the
same study, hand x-rays were obtained to evaluate changes
in cortical bone dimensions, as assessed by DXR, during
GH treatment. The study was conducted in accordance with
Good Clinical Practice guidelines and the Declaration of
Helsinki and with approval from appropriate ethical review
boards for each study centre.
Patient population
Young adults (18–25 years; body mass index, BMI, 18–
30 kg/m2) diagnosed with CO GHD, on the basis of at least
one stimulated test of GH secretion, were included in the
trial. All subjects had received GH treatment during
childhood until adult height was attained. Subjects with
isolated or only two (including GH) pituitary hormone
deficiencies were required to undergo a further provocative
GH test after their 16th birthday to confirm the diagnosis.
The required replacement therapy apart from GH was
performed at the discretion of the single investigator.
Subjects with three or more pituitary hormone deficiencies
were exempt from further testing. GH testing was carried
out according to current consensus guidelines at the time of
patient recruitment [14]. Patients were excluded from the
study if they had received GH treatment during the month
prior to randomisation, but information in the single
individual on the time since GH was discontinued was not
available. Other reasons for exclusion were serious cardiac,
hepatic or renal disease, uncontrolled hypertension, diabe-
tes, acromegaly, diseases that could affect bone metabolism
or any malignant tumour. Female subjects were excluded if
pregnant or lactating. For subjects with more than one
(other than GH) known deficient hypothalamic–pituitary
axis, replacement doses of thyroid, adrenal, gonadal and/or
antidiuretic hormone were to have been unchanged for at
least 6 months prior to attendance at the screening visit.
There were no significant differences between the treatment
and control groups regarding use of pituitary substitution
therapy [13].
Study protocol
Patients were randomised (2:1) to either two years' open-
label treatment with GH (Norditropin® SimpleXx®, Novo
Nordisk, Copenhagen, Denmark) or to an untreated control
group. GH was initiated at a starting dose of 0.2 mg/day
(males) and 0.4 mg/day (females). The dose was increased
to 0.6 and 0.9 mg/day at 1 month and raised again to 1.0
and 1.4 mg/day at 3 months, for males and females,
respectively, for the remainder of the study. The higher GH
dose was given to females since they require higher doses
than males to achieve normal insulin-like growth factor-1
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levels [15]. Dose reduction due to GH-related side effects
was allowed at the discretion of the investigator. A single
daily subcutaneous injection of GH was administered at
bedtime using a cartridge pen (NordiPen®, Novo Nordisk,
Copenhagen, Denmark). Patients in the control group
received no treatment during the study. The trial was
conducted as an open-label study and not placebo con-
trolled, since it was deemed unethical to subject young
adults to daily placebo injections for 24 months. Each
patient attended the clinic at the screening visit (1–5 weeks
before randomisation), the randomisation visit, and at 1, 3,
6, 12, 18 and 24 months. The study did not include any
information on dietary intake prior to treatment, and there
were no specific dietary requirements for the duration of the
study.
Measurements
Radiographs were obtained at months 0, 6, 12, 18 and 24.
DXR analysis (Sectra Imtec AB, Linkoping, Sweden)
requires a plain or digital radiograph of the non-dominant
hand [16]. In this study, plain radiographs were used and
sent to a central, blinded reading facility (The Osteoporosis
Unit, Hvidovre University Hospital, Copenhagen, Den-
mark). In order to secure standardised x-rays, a radio-
graphic manual was delivered to all centres, describing
positioning of the hand and forearm, film type, a film/
focus distance of 100 cm, and the use of 50 kV and 4–
8 mAs as exposure parameters. The radiographs were
captured as digital images using a flat-bed scanner
(600×600 dpi, 12-bit greyscale) and three regions of
interest (metacarpals 2, 3 and 4) were automatically
identified. In each of the three regions, the bone width
and inner diameter were measured symmetrically around
the centre of the metacarpals at a resolution of 117
lines/cm; the length ‘L’ is 1.5 cm for metacarpal 4—
1.8 cm for metacarpal 2 (Fig. 1). Bone width, endosteal
diameter, cortical thickness, metacarpal index (MCI) and
the areal cross-sectional moment of inertia (CSMI)





then calculated. The latter was included as a geometric
indicator of bone strength. The short-term precision of
DXR has previously been determined in 40 pre- and
postmenopausal women, demonstrating a coefficient of
variance (CV) value of 0.65% [17].
Statistical methods
Primary analysis of the treatment effect was performed with
an ANCOVA model including correction for baseline level
and the treatment effect on the logarithmic transformed
changes from baseline.
Analyses of the influence of gender, height, weight
and BMI were made by including them one by one in a
repeated measurement ANCOVA model with treatment,
visit, interaction between treatment and visit and
baseline level as fixed effects and subject as a random
effect. The correlations between radiogrammetric and




Patients (n=160) were randomised to receive GH (n=109)
or no treatment (n=51). Baseline patient demographics as
well as baseline values for bone parameters by sex and
treatment group were not different between groups (Table 1).
There were 19 (17.4%) withdrawals in GH-treated patients
and 11 (21.6%) withdrawals in the control group. The most
common reason for withdrawal from the study was patient
decision. Only five patients withdrew due to adverse events,
details of which can be found in the previous publication
[13]. Mean GH dose (standard deviation, SD) at study end
was 17.9 μg/kg/day (6.3).
Efficacy
In young adults with CO GHD previously treated with
GH until final height, reinstitution of GH for 24 months
was associated with a marked increase in cortical
Fig. 1 Principles of digital x-ray radiogrammetry. Using a standard x-
ray, the region of interest is automatically detected. From the density
curve (right), the external and internal diameters are detected (117
lines/cm). The reported bone width (W), cortical thickness (T) and
endosteal diameter are the averages of these measurements.
Coefficient of variation (CV) 0.65%
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thickness compared to a matched control group (treat-
ment difference [GH-control] [95% CI]) (6.43% [95%
CI, 3.34, 9.61], p<0.0001). This increase was the result
of both cortical expansion and endosteal bone growth.
However, while the external diameter increased equally in
GH-treated and control groups (estimated treatment
difference 0.68% [95% CI −1.17, 2.57], NS) a significant
treatment difference in favour of GH was found in the
endosteal diameter, with a greater reduction in GH-treated
as compared to untreated patients (−4.64 mm [95% CI
7.15, 2.05], p=0.0006) (Fig. 2). A gender effect, which
was not correlated to any treatment effect (p=0.057) with
cortical thickness being greater in males than in females
(0.19 vs. 0.18), was also demonstrated. Finally, a
significant influence of height was found (p=0.0002);
the taller a subject, the greater the cortical thickness.
As an index of bone biomechanical competence, the
CSMI was calculated showing a significant increase over
time in both GH-treated patient and controls (p<0.0001)
(Fig. 2). The difference between the two groups did not
reach statistical significance, although there was a trend
towards a greater increase in GH-treated patients (treatment
difference, 4.53 [−2.96, 12.59], p=0.2404). A significant
effect of baseline BMD was found (−0.23 [−0.31 to −0.14)],
p<0.0001).
GH treatment was associated with greater increase in
MCI compared to the control group where this value
remained more or less constant during the 24-month
study period (estimated treatment difference, 6.14%
[3.95, 8.38], p<0.0001) (Fig. 3). In order to evaluate to
what extent the radiogrammetry measurements reflected
skeletal changes in general, the correlations between
radiogrammetric and densitometric measurements are
shown in Table 2.
Discussion
The main finding of the present study was that GH
substitution, after achievement of final height in young
adults with CO GHD, is associated with a significant
increase in cortical bone thickness. The observed reduction
in endosteal diameter in GH-treated patients in this study
suggests that the increase results from endosteal bone
growth rather from periosteal apposition. While there is
no one single cause of bone fragility, fewer or thinner
trabeculae and thin cortices, all play their part in low peak
bone density [18]. In early adulthood, material and
structural strength is maintained by remodelling, the focal
replacement of old with new bone. During ageing,
concurrent bone formation on the outer (periosteal) cortical
bone surface partly compensates for bone loss. Although
the structural basis of bone fragility is determined partly by
genetic and environmental factors, growth during the
pubertal and early adult years has a significant influence
on bone strength in later years. Hence, a GH-induced
reduction in endosteal diameter may, potentially, have
beneficial effects on cortical bone strength [19, 20], thereby
reducing the risk of bone fragility later in life [21]. Limited
data are currently available on the growth patterns of
cortical bone during normal adolescence and in patients
with CO GHD, and our findings therefore also contribute to
the understanding of cortical bone development during
growth.
There are few data on changes in cortical bone density
with GH therapy in patients with CO GHD. Using
peripheral quantitative computed tomography, Schweizer
et al. [22] reported that 12 months of GH therapy was
associated with an increase in both outer and inner
diameters of the radius, as well as decreased cortical
Table 1 Baseline characteristics of randomised patients by treatment group, mean (SD)
Growth hormone group (n=109) Control group (n=51)
Male Female Total Male Female Total
n (%) 65 (60) 44 (40) 109 (100) 34 (67) 17 (33) 51 (100)
Age (years) 21.0 (2.4) 21.2 (2.2) 21.1 (2.3) 21.4 (2.2) 21.4 (2.1) 21.4 (2.1)
Height (cm) 172.4 (7.4) 155.8 (7.2) 165.7 (11.0) 170.3 (7.6) 162.1 (8.7) 167.5 (8.8)
Weight (kg) 69.6 (13.6) 54.6 (11.1) 63.5 (14.6) 68.5 (13.0) 59.6 (10.7) 65.5 (12.9)
BMI (kg/cm2) 23.3 (3.5) 22.4 (3.4) 22.9 (3.5) 23.5 (3.6) 22.6 (3.3) 23.2 (3.5)
Bone width (cm) 0.820 (0.076) 0.727 (0.049) 0.783 (0.080) 0.813 (0.073) 0.726 (0.076) 0.784 (0.084)
Endosteal diameter (cm) 0.459 (0.71) 0.416 (0.65) 0.442 (0.72) 0.427 (0.088) 0.409 (0.074) 0.421 (0.083)
Cortical thickness (cm) 0.186 (0.027) 0.161 (0.024) 0.176 (0.029) 0.200 (0.028) 0.163 (0.027) 0.188 (0.032)
Metacarpal index (mm/mm) 0.44 (0.06) 0.43 (0.07) 0.44 (0.06) 0.48 (0.08) 0.44 (0.07) 0.47 (0.08)
Areal cross-sectional moment of inertia
(mm4×1,000)
21 (8) 12 (3) 17 (7) 20 (7) 13 (5) 18 (7)
No significant difference between groups was found in demographic data or radiographic measurements
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thickness. The impact of GH on cortical bone might be
different after epiphyseal closure and cessation of longitu-
dinal bone growth.
The findings of this study are in agreement with the
earlier reported densitometry findings of the same popula-
tion [13], showing an increase in lumbar spine BMD of
3.5% and total hip BMD of 2.4% during GH therapy.
Interestingly, some studies report a reduction in bone
density during the first year of GH therapy, which is likely
caused by an increase in remodelling space and a temporary
reduction in bone mass and size [3, 23, 24]. Longer
treatment periods show increased bone formation as the
areal bone density tends to fall during the first 6 months of
treatment and reaches baseline levels again between 6 and
12 months [13]. In the present study, in which only cortical
bone is encountered, a linear increase in cortical area was
observed from the very start of treatment. Despite only a
marginal increase in bone width being observed in our
study, there was a pronounced reduction in the inner bone
diameter. This reduction leads to an increase in cortical
thickness and a tendency towards an increase in strength, as
calculated by the CSMI. Furthermore, our data support that
the initial loss of areal bone density due to increased
remodelling was only marginal in cortical bone compared
with BMD of the spine and total hip, where a trabecular
component was part of the region of interest. Histological
evaluation after GH treatment for 1 year in CO GHD
patients has shown increased trabecular bone turnover, but
not a positive bone balance [25]. However, a different
pattern is likely to be seen in cortical bone and after a
longer duration of treatment [13].
Fig. 3 Change in metacarpal index (2CT/W [millimetres per milli-
metre]) by treatment group and by gender
Fig. 2 Changes in metacarpal bone dimensions over 24 months
(estimated mean ± 95% confidence interval). Solid line growth
hormone treatment group, dashed line untreated group. a Bone width
(centimetres), b endosteal diameter (centimetres), c cortical thickness
(centimetres), d CSMI (×1,000). p values indicate treatment difference
from baseline to end of trial. p<0.0001
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To obtain normal bone growth and optimal peak bone
mass, the interplay of GH and gonadal hormones through
late childhood and puberty is essential. Consequently, GHD
as well as hypopituitarism in adults is associated with low
bone mass and an increased risk of fractures [26–29]. While
the impact of gonadal hormones on bone growth is
diminished after epiphyseal closure, GH continues to play
an important role in reaching peak bone mass several years
later. Consequently, patients with CO GHD are lacking an
important factor if GH treatment is stopped when final
height is reached. Until now this has been the normal
procedure for most CO GHD patients. Discontinuation of
GH treatment after attainment of adult height may
compromise further bone growth [11, 30]. Indeed, changes
in cortical bone when GH treatment is reinstituted, as found
in the present study, are the reverse of the age-related
changes in bone seen in later adult life [31] and may
therefore leave the CO GHD patients better protected
against cortical bone fragility as they age. The changes in
cortical bone growth may also have been influenced by
dietary factors. No data on diet are available, but the
randomisation process is likely to have minimised such
bias.
Studies evaluating changes in lumbar spine BMD
indicate that despite a lower areal density in CO GHD
patients, the volumetric density is not lower [3]. Conse-
quently, CO GHD leads to insufficient growth of bone size,
but not low bone mineral content [32]. The increased
fracture risk described in CO GHD [5] is consequently
related to small bones rather than to low BMD.
Using radiogrammetry, comparison with normative data
from other studies should be interpreted with caution due to
the potential influence of differences in exposure settings,
but the settings used in the present study do not differ
substantially from those used by Toledo and Jergas [33]. A
comparison of cortical dimensions in the GHD patients
with the female normative data from the study reported by
Toledo and Jergas [33] showed smaller bones with a thinner
cortical shell in the female CO GHD patients. After 2 years
of GH therapy, bone dimensions of treated females
approached those of healthy women, but no gender
difference following treatment was found in the ratio of
cortical thickness to bone width, as measured by MCI.
Furthermore, while there was a similar increase in bone
width in GH-treated subjects and controls, changes in the
endosteal diameter were significantly greater in the GH-
treated subjects. This might indicate that the main effect of
GH on cortical bone growth is mainly on the inner
surfaces.
DXR allows detailed non-invasive evaluation of
cortical bone dimensions and can therefore be used as
a supplement to bone densitometry. It measures the
metacarpal dimensions with high precision, and there-
fore, also smaller changes can be detected. The present
data clearly show that this technique provides meaning-
ful information on cortical bone dimensions using
simple radiographs of the hand. Also, the effect of GH
can be detected after 12 months of treatment compared
with conventional densitometry, where the effects are
only detectable much later due to an initial decline in
areal bone density. A potential weakness of the method
is that only metacarpal bone is measured and may
therefore not be representative of cortical bone changes
in general. However, it has previously been shown that
the same measurements at the metacarpals predict
fracture risk at both hip and spine [34]. It is therefore
likely that the measured changes reflect a generalised
effect on bone, at least in patients with osteoporosis. In the
present study, significant correlations between baseline
cortical thickness and baseline BMD of the hip and spine,
as well as changes in cortical thickness and changes in
spine and hip BMD, were found, indicating that this is
probably also the case for CO GHD patients. Further
studies are needed to evaluate this finding in more depth.
In conclusion, these data showed that in patients with
CO GHD, 2 years' treatment with GH after attainment of
final height was associated with beneficial changes in
cortical bone dimensions which are the reverse of those
seen with age-related bone loss. Provided that the improve-
ments in cortical thickness are maintained over longer time
periods, GH treatment of CO GHD patients might reduce
the risk of cortical bone fragility later in life.
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Table 2 Correlations between
cortical thickness measured
by radiogrammetry at the meta-
carpal bones and densitometry
measurements at the spine
and hip [13]
R^2 p value
Cortical thickness at baseline vs. BMD spine at baseline Entire group 0.25 <0.0001
Cortical thickness at baseline vs. BMD total hip at baseline Entire group 0.18 <0.0001
Change in cortical thickness vs. change in BMD spine GH-treated 0.07 0.0103
Change in cortical thickness vs. change in BMD spine Untreated 0.09 0.0806
Change in cortical thickness vs. change in BMD total hip GH-treated 0.13 0.0005
Change in cortical thickness vs. change in BMD total hip Untreated 0.02 0.3824
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